
- Gemina raises $2.2m via a non-brokered private placement
- Placement is oversubscribed
VANCOUVER, BC, October 25, 2021 – Syniad Innovations Inc (“Syniad”) is pleased to announce that Gemina Laboratories Ltd. (“Gemina”) has successfully closed a non-brokered private placement. The placement, which was oversubscribed, raised gross proceeds of $2.2m at a price per share of $0.55 per Unit. Each Unit consists of one common share (a “Common Share”) of Gemina and one-half of one Common Share purchase warrant (each whole warrant, a “Warrant”). Each Warrant will entitle the holder thereof to acquire one Common Share at an exercise price of $0.80 per Common Share for a period of 24 months from the date of issuance, subject to acceleration if the trading price of the Common Shares equals or exceeds $2.00 for a period of 10 consecutive days.
Syniad co-founded Gemina in 2020, to create a world-leading biosensing company. Gemina’s objective is to deliver diagnostic testing at the point of need. Its technology platform has the potential to address a wide range of pathogens, for instance, the rapid testing of COVID-19, Influenza and a variety of other viruses and conditions.
Commenting on today’s announcement, John Davies, Syniad’s CEO, said, “Today’s financing is another great step forward for Gemina as it advances its first product – a rapid diagnostic test – based on its proprietary biosensing platform.”
Latest Posts

Anodyne Chemistries Secures Trademark for “Anozyme”
Read More
Syniad’s Brokkr Appoints Richard Shaw to its Advisory Board
Read More
Syniad’s Brokkr Appoints Samantha Espley to its Advisory Board
Read More